[246,247,248,249,250,251,252,253] have validated microtubule-stabilizing agents (e.g., EpoD [246,247,248], NAP [249,250], and CNDR-51997 [251]) and actin modulators (e.g., fasudil [252]) in mitigating AD-associated tau pathology and restoring synaptic plasticity, with early-phase clinical trials demonstrating feasibility (Table 1). Here, MAPT is linked to Alzheimer disease.